At present, several clinical trials are active, including retatrutide maintenance studies lasting over 80 weeks and head-to-head trials comparing retatrutide to tirzepatide
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial Multi-receptor agonists that target the glucagon, glucose-dependent insulinotropic polypeptide (GIP), and glucagon-like peptide 1 (GLP-1) receptors may improve outcomes in type 2 diabetes because this condition is linked to hyperglycemia and obesity
Health Promot Chronic Dis Prev Can
After battling severe stress-induced health issues during her medical studies, she dedicated her career to uncovering the root causes of chronic diseases